Immune-mediated cholangitis: is it always nivolumab’s fault?

  • Francesco Gelsomino
  • Giovanni Vitale
  • Andrea Ardizzoni
Letter to the Editors


Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.


  1. 1.
    Kashima J, Okuma Y, Shimizuguchi R, Chiba K (2018) Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother 67:61–65. CrossRefPubMedGoogle Scholar
  2. 2.
    Kawakami H, Tanizaki J, Tanaka K et al (2017) Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 35:529–536CrossRefPubMedGoogle Scholar
  3. 3.
    Gelsomino F, Vitale G, D’Errico A, Bertuzzi C, Andreone P, Ardizzoni A (2017) Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol 28:671–672CrossRefPubMedGoogle Scholar
  4. 4.
    European Association for the Study of the Liver (2009) EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 51:237–267CrossRefGoogle Scholar
  5. 5.
    Haanen JBAG., Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K, ESMO Guidelines Committee (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv119-iv142CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Francesco Gelsomino
    • 1
  • Giovanni Vitale
    • 1
  • Andrea Ardizzoni
    • 1
  1. 1.Medical Oncology UnitPoliclinico S. Orsola-Malpighi, University of BolognaBolognaItaly

Personalised recommendations